Utility of paired box gene 8 (PAX8) expression in fluid and fine‐needle aspiration cytology
暂无分享,去创建一个
[1] R. Attanoos,et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum , 2002, Histopathology.
[2] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[3] A. Gown,et al. Wilms Tumor Gene Product: Sensitive and Contextually Specific Marker of Serous Carcinomas of Ovarian Surface Epithelial Origin , 2004, Applied immunohistochemistry & molecular morphology : AIMM.
[4] Luis Chiriboga,et al. Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas , 2008, The American journal of surgical pathology.
[5] B. D. De Young,et al. MOC‐31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells , 1999, Cancer.
[6] R. Walker,et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .
[7] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[8] I. Kawase,et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.
[9] H. Sasano,et al. Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. , 2005, The Tohoku journal of experimental medicine.
[10] S. Mundlos,et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. , 1992, Development.
[11] N. Bowen,et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. , 2007, Gynecologic oncology.
[12] N. Jhala,et al. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. , 2001, American journal of clinical pathology.
[13] G. Pinkus,et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. , 2002, American journal of clinical pathology.